FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
62.596,95 +1.063,59 (+1,73%)
Molecular Partners AG (0QXX.L)
| Chiusura precedente | 5,93 |
| Aperto | 5,90 |
| Denaro | 0,00 x 0 |
| Domanda | 0,00 x 0 |
| Min-Max giorno | 5,90 - 5,97 |
| Intervallo di 52 settimane | 3,04 - 6,17 |
| Volume | |
| Media Volume | 6.578 |
| Capitalizzazione | 106,6M |
| Beta (mensile su 5 anni) | 0,67 |
| Rapporto PE (ttm) | 0,02 |
| EPS (ttm) | 3,31 |
| Prossima data utili | 26 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireMolecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions transferrable across the platform and to a broad range of tumor targets RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors and for expansion of targets amenable to radiotherapy ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDA
- GlobeNewswire
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable safety profile in patients with advanced solid tumors, supporting future combination studies with potential partners; presently finalizing recruitment of weekly dosing reg
